Exchange: NASDAQ·Updated 07:30 PM EST

RNXT News

News
all
press releases
RenovoRx (NASDAQ:RNXT) Stock: Insider Ramtin Agah Acquires 50,000 Shares
RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) CMO Ramtin Agah acquired 50,000 shares of the company's stock in a transaction dated Monday, November 16th. The shares were bought at an average cost of $0.93 per share, with a total value of $46,500.00. Following the purchase, the chief marketing...
MarketBeat
RenovoRx (NASDAQ:RNXT) Stock: Insider Ramtin Agah Acquires 50,000 Shares
RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) CMO Ramtin Agah acquired 50,000 shares of the company's stock in a transaction dated Monday, November 16th. The shares were bought at an average cost of $0.93 per share, with a total value of $46,500.00. Following the purchase, the chief marketing...
MarketBeat
More News
RenovoRx (RNXT) delivered earnings and revenue surprises of -40.00% and +1.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.read more...
Benzinga
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Travere (TVTX) delivered earnings and revenue surprises of -164.29% and +10.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +5.29% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.